Well done to Alexandra, and the rest of the team! It was a very punchy presentation. I like the fact that she alluded to preclinical data which is of great interest to Big Pharma.
I was very impressed, and happy to hold as the story unfolds. I also got the impression that things are happening behind the scenes.
This is one stock where I would rather be twelve months early, than one day late.
